Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Key Takeaways From Vivus' Bad Quarter

From the smallest biotech to the biggest pharmaceutical stock, The Motley Fool's Market Checkup covers the health-care sector's biggest headlines, hottest market movers, and Obamacare's ongoing rollout.

In this segment from Thursday's episode, health-care analyst David Williamson takes a look at the third-quarter earnings report from Vivus (NASDAQ: VVUS  ) . Shares fell more than 12% on the news that the company's revenue from its drug Qsymia was nowhere near what investors were hoping for. While the company showed 35% quarter-to-quarter growth, this, too, fell drastically short of the exponential growth investors were hoping for from a pharmaceutical company with a potentially blockbuster new drug rollout. David looks closely into Vivus' prospects, and lists a few other headwinds investors should be aware of.

Two game-changing biotechs
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report, "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Follow David on Twitter: @MotleyDavid.

Read/Post Comments (3) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 08, 2013, at 6:20 PM, biogemfinder wrote:

    Where is the permabasher RSdribble? I am sure he will show up in a few days after he is done licking his wounds!

  • Report this Comment On November 10, 2013, at 10:55 AM, marpieslice09 wrote:

    rs dribble is comforting spencer and adam fraud.

    vvus owes more then even possible to begin paying back.with zero sales,,,cfo leaving,multiple class actions...figure 3 months vvus gone

  • Report this Comment On November 11, 2013, at 1:31 PM, eaglesnaps wrote:

    ^^^^^ Dumbest comment ever gone in 3 months lol... vivus will get a partner stock will go up then time to sell... if u bought at the bottom like me when everyone else panicked the other day congrats are in order u will cash in

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2719772, ~/Articles/ArticleHandler.aspx, 9/27/2016 11:46:16 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,173.24 78.41 0.43%
S&P 500 2,154.44 8.34 0.39%
NASD 5,288.33 30.84 0.59%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/27/2016 11:30 AM
VVUS $1.20 Down -0.05 -3.63%
VIVUS CAPS Rating: **
ARNA $1.77 Up +0.04 +2.31%
Arena Pharmaceutic… CAPS Rating: ***